Evening Primrose Skin Randomized Trial: What the Evidence Says

Quick Answer

Evening Primrose Skin Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Napheys in 1981 described it as an "unpleasant train of symptoms that can be alarming, painful, and often entailing sad consequences, though rarely fatal." He found that physicians tended to ridicule these complaints. [Thevi Thanigasalam (2024); evidence level 1]
• Randomized trials have not only shown no benefit in HRT for menopause but also shown that there is an increased risk of coronary heart disease (CHD) and breast cancer. [Thevi Thanigasalam (2024); evidence level 1]
• This geographical variation suggests important underlying differences in risk factors, healthcare access, diagnostic practices and cultural attitudes toward breast health that warrant further investigation. [Arya Avneesh (2025); evidence level 4]
• By examining the epidemiology of mastalgia in rural Ujjain hospital, healthcare providers and policymakers can better understand the local disease burden, identify high-risk populations and develop culturally appropriate interventions to address this common but often overlooked women's health issue. [Arya Avneesh (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For evening primrose skin randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Thevi Thanigasalam (2024). Evening Primrose Oil for Menopause Hot Flashes: Systematic Review and Meta-Analysis. DOI: 10.6118/jmm.23038. PMCID: PMC11745733. PMID: 39829189. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC11745733/
• Arya Avneesh (2025). Epidemiology of Mastalgia in rural populations: A study from Ujjain, India. DOI: 10.6026/973206300212448. PMCID: PMC12697446. PMID: 41393452. License: https://creativecommons.org/licenses/by/3.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC12697446/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.